공시 • Jul 17
Blueprint Medicines Corporation(NasdaqGS:BPMC) dropped from NASDAQ Biotechnology Index Blueprint Medicines Corporation has been dropped from the NASDAQ Biotechnology Index. 공시 • Jun 13
Blueprint Medicines Corporation Announces Data Reinforcing Sustained Clinical Efficacy and Well-Tolerated Safety Profile of Long-Term AYVAKIT® (avapritinib) Treatment at 2025 EHA and EAACI Congresses Blueprint Medicines Corporation announced data presentations reflecting over a decade of collaboration with clinical experts and patient advocates to transform the treatment of systemic mastocytosis (SM). Key results continue to position AYVAKIT®?/AYVAKYT®? (avapritinib) as the durable standard of care across indolent and advanced SM, and highlight the real-world burden of the disease, reinforcing the importance of treating with a therapy that addresses the root cause of SM. These data will be reported at the 2025 European Hematology Association (EHA2025) Hybrid Congress, being held June 12 to 15 in Milan, Italy, and the European Academy of Allergy and Clinical Immunology (EAACI) Congress 2025, being held June 13 to 16 in Glasgow, United Kingdom. PIONEER Three-Year Data: Durable Clinical Benefits and Consistent Safety Profile with Long-Term AYVAKIT Use in ISM: As previously presented, AYVAKIT demonstrated robust improvements through 144 weeks in overall symptom and symptom domain measures (skin, gastrointestinal, neurocognitive) representative of real-world patient impacts. AYVAKIT showed a well-tolerated safety profile and a low discontinuation rate due to treatment-related adverse events (TRAEs; 3%) with a median of three years of exposure, and some patients out to five years on therapy. Common TRAEs included low-grade edemas, headache and nausea. In newly reported data, AYVAKIT showed sustained clinical benefits across quality-of-life measures that reflect general health status and are broadly recognized by allergists/immunologists, validating previously presented results from the disease-specific, Mastocytosis Quality of Life (MC-QoL) questionnaire. PATHFINDER/EXPLORER Multi-Year Data: Long-Term Survival Benefits of AYVAKIT in Advanced SM: AYVAKIT showed prolonged overall survival (OS) in PATHFINDER and EXPLORER, when indirectly compared to real-world data for midostaurin from the German Registry on Disorders of Eosinophils and Mast Cells (GREM). AYVAKIT led to meaningful survival benefits in patients across all prognostic categories (low, intermediate and high risk), per the Revised Mutation-Adjusted Risk Score (MARS-R) – a new OS risk assessment tool for advanced SM. Conducted in collaboration with University Hospital Mannheim, the analyses validate the MARS-R tool's ability to assess OS risks in advanced SM patients treated with AYVAKIT or midostaurin, using clinical and genetic parameters. The MARS-R was developed to inform physician care decisions based on individual patient needs. PRISM Data: Substantial Disease Burden Across Broad Population of Patients with ISM: PRISM is one of the largest studies characterizing the impact of SM from both patient and clinical perspectives. Across the spectrum of disease severity, patients with ISM experienced physical, social and emotional challenges that caused meaningful disruption to their daily lives. Patients reported a broad constellation of disease-related impacts, including limitations to physical activities, work/college and relationships; problems with pain/discomfort and anxiety/depression; and adjustments in their daily lives to avoid certain foods, extended sun exposure and smells. 공시 • Jun 02
Sanofi (ENXTPA:SAN) agreed to acquire Blueprint Medicines Corporation (NasdaqGS:BPMC) from Sixth Street Partners, LLC for $8.72 billion. Sanofi (ENXTPA:SAN) agreed to acquire Blueprint Medicines Corporation (NasdaqGS:BPMC) from Sixth Street Partners, LLC for $8.72 billion on June 2, 2025. Under the terms of the acquisition, Sanofi will pay $129.00 per share in cash at closing, representing an equity value of approximately $9.1 billion. Blueprint shareholders also will receive one non-tradeable contingent value right (CVR) which will entitle the holder to receive two potential milestone payments of $2 and $4 per CVR for the achievement, respectively, of future development and regulatory milestones for BLU-808. Sanofi will pay $344.237175 million for 2.549905 million for Restricted stock units. Sanofi will pay $39.868875 million for 0.295325 million for Performance-based restricted stock units. Sanofi will pay $413.578677 million for 6.925296 million options. The total equity value of the transaction, including potential CVR payments, represents approximately $9.5 billion on a fully diluted basis. The consummation of the tender offer is subject to customary closing conditions, including the tender of a number of shares of Blueprint common stock representing at least a majority of the outstanding shares of Blueprint common stock, the receipt of required regulatory approvals, and other customary conditions. Sanofi currently expects to complete the acquisition in the third quarter of 2025.
Sanofi plans to finance the transaction with a combination of cash on hand and proceeds from new debt. The tender offer is not subject to any financing condition. It is immediately accretive to gross margin and accretive to business operating income and EPS after 2026.
Upon termination of the Merger Agreement, (i) Sanofi under specified circumstances, including termination following a final order, decree or ruling arising in connection with certain antitrust or foreign investment laws, will be required to pay the Blueprint Medicines a termination fee in the amount of $500 million; and (ii) Blueprint Medicines under specified circumstances, including termination by the Blueprint Medicines to accept and enter into an agreement with respect to a superior proposal, will be required to pay Parent a termination fee in the amount of $318 million.
The Company Board unanimously (i) determined that the Merger Agreement and the transactions contemplated thereby, including the Offer and the Merger, are advisable and fair to, and in the best interests of, the Company and the holders of the Shares, (ii) adopted the Merger Agreement and approved the execution, delivery and performance by the Company of the Merger Agreement and the consummation of the transactions contemplated thereby, including the Offer and the Merger, and (iii) resolved to recommend that the holders of the Shares accept the Offer and tender their Shares pursuant to the Offer and the transaction is subject to approval of Blueprint Medicines.
Michael J. Aiello; Sachin Kohli of Weil, Gotshal & Manges LLP, Paris served as legal advisor to Sanofi, and Stuart M. Cable, Lisa R. Haddad and James Ding of Goodwin Procter LLP served as legal advisor to Blueprint Medicines. Centerview Partners LLC acted as financial advisor to Blueprint Medicines Corporation. 
